Transaction

SPE Capital, EBRD, Proparco, and BIO's Investment in Orchidia Pharmaceutical Industries' Operations in Egypt

Announced
11 March 2026
Target
Orchidia Pharmaceutical Industries S.A.E.
Value
Undisclosed
Asset class
Private Equity
Type
Investment
Instrument
Ordinary Shares (Equity)
Lead investors
SPE Capital Partners
Investors
SPE Capital Partners, Proparco, European Bank for Reconstruction and Development (EBRD), Belgian Investment Company for Developing Countries (BIO)
Sector
Healthcare / Pharmaceuticals
Markets
Egypt

About the target

Orchidia Pharmaceutical Industries S.A.E. is an Egypt-based pharmaceutical manufacturer specialising in ophthalmic products. Established in 1993, the company operates a 6,000 square metre manufacturing facility in Al-Obour City, Cairo, which is considered one of the largest ophthalmic-focused plants in the Middle East. The facility has a production capacity of 35 million units annually. Orchidia ranks second in the Egyptian ophthalmic market and has achieved the highest growth rate in this segment. Its portfolio comprises 35 ophthalmic drugs and three CE-marked medical devices, supported by a pipeline of 60 additional ophthalmic drugs in development. Beyond ophthalmology, the company also produces lens care solutions, cosmeceuticals, and supplements. Orchidia is certified for WHO-GMP implementation by the Egyptian Ministry of Health and other regulatory authorities in the Middle East and Africa, and holds ISO 9001, ISO 14001, and OHSAS certifications. The company maintains Quality Management Systems and Environmental Health and Safety frameworks that comply with international standards, supporting export activities to over 40 countries across Africa and the Middle East.

Sources

  1. www.africaprivateequitynews.com
  2. Partner Researchers